<DOC>
	<DOCNO>NCT01338415</DOCNO>
	<brief_summary>The objective FUTURE 3 Study Extension evaluate long-term safety , tolerability efficacy pediatric formulation bosentan two versus three time day child Pulmonary Arterial Hypertension ( PAH ) .</brief_summary>
	<brief_title>FUTURE 3 Study Extension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>1 . Patients complete FUTURE 3 core study ( AC052373 ) prematurely discontinue due PAHprogression , bosentan permanently discontinue 2 . Patients tolerate bosentan pediatric formulation bosentan consider beneficial end FUTURE 3 core study ( AC052373 ) 3 . Signed informed consent parent legal representative prior studymandated procedure . 1 . Known intolerance hypersensitivity bosentan excipients dispersible bosentan tablet 2 . Any clinically significant laboratory abnormality preclude continuation bosentan therapy 3 . Pregnancy 4 . AST and/or ALT value &gt; 3 time upper limit normal range ( ULN ) 5 . Moderate severe hepatic impairment , i.e. , ChildPugh Class B C 6 . Premature permanent study drug discontinuation FUTURE 3 core study ( AC052373 ) 7 . Any major violation FUTURE 3 core study ( AC052373 ) protocol .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>pediatric</keyword>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>bosentan</keyword>
	<keyword>Tracleer</keyword>
</DOC>